[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chemotherapy-related-cognitive-impairment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chemotherapy-related-cognitive-impairment":111},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100555175","phase-4-effects-of-dl-3-n-butylphthalide-on-chemotherapy-induced-cognitive-impairment-100555175",false,"NCT06508671","Effects of DL-3-n-butylphthalide on Chemotherapy-Induced Cognitive Impairment","Effects of DL-3-n-butylphthalide on Chemotherapy-Induced Cognitive Impairment (NBP CICI)：a Prospective, Randomized, Double Blinded, Multicenter, Placebo Controlled Study","Inclusion Criteria:\n\n1. Treatment with paclitaxel drugs (such as paclitaxel\u002Fdocetaxel\u002Falbumin-based paclitaxel, etc.) or platinum-based chemotherapy (cisplatin), and not combined with other chemotherapy drugs; (Cancer type is not limited)\n2. Sign the informed consent and understand the purpose and significance of the study;\n3. Aged between 35 and 80 years old;\n4. Ability to complete the questionnaire on their own or with assistance;\n5. Complaints of cognitive impairment involving memory and\u002For other cognitive areas lasting for at least 3 months;\n6. Cancer treatment has been completed and is considered curable, with the exception of endocrine therapy after chemotherapy;\n7. MMSE score: 18-26;\n8. Clinical Dementia Rating (CDR) score: 0.5-2;\n9. Fluent in Chinese;\n10. No visual or hearing impairment;\n11. Did not participate in another intervention study within 6 months prior to commencing this study;\n\nExclusion Criteria:\n\n1. Diagnosed with a cognitively impaired disease, such as Alzheimer's disease;\n2. Patients will be excluded from fMRI testing if they are claustrophobic, have MRI contraindications such as pacemakers or metal implants, and patients who did not undergo fMRI testing may still participate in clinical trials if all other enrollment criteria are met;\n3. Take medications that may affect cognitive function\n4. History of brain metastases or other brain tumors;\n5. History of stroke or severe head trauma;\n6. History of epilepsy or other seizures;\n7. Pregnant or considering becoming pregnant;\n8. Any active nervous system or untreated\u002Funremitted mental disorder (such as active major depressive disorder or other major mental disorder described in the DSM-5, allowing treatment of depression if treatment is stable)\n9. Any history of alcohol or drug abuse or dependence within the past 2 years;\n10. Any major systemic disease or unstable medical condition that may cause difficulty in complying with the protocol, including: a history of myocardial infarction or instability in the past year, serious cardiovascular disease (including angina or congestive heart failure with resting symptoms, or clinically significant abnormalities in the electrocardiogram), clinically significant and\u002For unstable lung, gastrointestinal, liver or kidney disease;\n11. Have taken any non-research drugs to improve cognitive function within 4 weeks prior to enrollment;\n12. Have taken butylphthalein in the past 30 days.","ALL","35 Years","80 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Chemotherapy-related cognitive Impairment (CICI) is a series of neurocognitive deficits experienced during and after cancer chemotherapy. Studies have reported that CICI affects 25% to 75% of survivors and can persist for years after chemotherapy is discontinued, causing more severe progressive manifestations and placing a heavy burden on families and society. Numerous studies have proposed several potential mechanisms and etiologies for CICI, including direct neurotoxicity, disruption of the blood-brain barrier, reduced hippocampal neurogenesis, white matter abnormalities, secondary neuroinflammatory responses, and increased oxidative stress. At present, there is no clear and effective diagnosis and therapy for CICI, and how to diagnose and treat cognitive impairment caused by chemotherapy effectively is still the focus and difficulty.\n\nBased on the previous consensus on the application of dl-3-n-butylphthalide, butylphthalein can play a neuroprotective role by reducing oxidative stress and inflammatory response, inhibiting neuronal apoptosis, improving mitochondrial function and other mechanisms, and significantly improve the performance of the central nervous system caused by cerebral ischemia and vascular dementia. However, the increase of neuroinflammatory response and oxidative stress is precisely one of the potential mechanisms of CICI pathogenesis. Therefore, based on the above findings, this study hypothesized that dl-3-n-butylphthalide would also have considerable efficacy in the treatment of CICI.",[27,28],"Chemotherapy-Related Cognitive Impairment","DL-3-n-butylphthalide","NOT_YET_RECRUITING","2024-07-14",{"date":32,"type":33},"2024-07-18","ACTUAL",{"date":35,"type":21},"2024-07",{"date":37,"type":21},"2026-12",{"name":39,"class":40},"First Hospital of China Medical University","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100534078","aerobic-dance-during-chemotherapy-in-breast-cancer-patients-with-cognitive-impairment-100534078","NCT06234150","Aerobic Dance During Chemotherapy in Breast Cancer Patients With Cognitive Impairment","Aerobic Dance During Chemotherapy in Breast Cancer Patients With Cognitive Impairment（ADANC）","ADANC","Inclusion Criteria:\n\n* 18-65 years old\n* Newly diagnosed, histologically confirmed, resected stage I-IIIa BC\n* Scheduled for chemotherapy with Epirubicin+ Cyclophosphamide (EC) regimen\n* Presence of objective cognitive decline\n\nExclusion Criteria:\n\n* Regular exercise habits (exercise at moderate intensity for 30 minutes a day, 3 days a week, for at least 3 months.),\n* Motor dysfunction\n* Alzheimer's disease\n* Vascular dementia","FEMALE","18 Years","65 Years",{"count":53,"type":21},90,[55],"NA","The goal of this clinical trial is to learn about breast cancer patients. The main questions it aims to answer are:\n\n* Does Aerobic Dance During Chemotherapy Improve Cognitive Function in Breast Cancer Patients？\n* Does the efficacy of aerobic dance differ from fast walking of equal intensity？ Recruited patients will be randomly assigned to three groups: (1) aerobic dance group, (2) fast walking group, and (3) usual care group.\n\nThe aerobic dance and fast-walking groups participated in supervised exercise lasting 50 minutes thrice a week for 12 weeks.\n\nThe goal of this study's findings is to develop practical strategies for managing breast cancer-related cognitive impairment.",[58,59,27,60,61],"Breast Neoplasms","Exercise Therapy","Cognitive Dysfunction","Dance Therapy","2024-02-17",{"date":64,"type":33},"2024-02-20",{"date":66,"type":21},"2024-04-01",{"date":68,"type":21},"2027-01-01",{"name":70,"class":40},"The First Affiliated Hospital with Nanjing Medical University",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":16,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":96,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":71},"100503846","investigating-cognitive-impairment-in-young-patients-with-cancer-prospectively-100503846","NCT05840575","Investigating Cognitive Impairment in Young Patients With Cancer Prospectively","A Multidisciplinary Neuroscience Approach to Investigate Cognitive Impairment in Young Patients With Cancer Prospectively","MyBrain","Inclusion Criteria:\n\n* Patients who are newly diagnosed with a non-CNS cancer and will undergo chemotherapy at University Hospital Copenhagen, Rigshospitalet.\n* At the age of 7-29 years at diagnosis\n* Each patient is matched (1:1) with a control participant within 24 months of age. The controls are recruited from the patient's own social circle and can be a friend, partner, or close family (sibling or cousin).\n\nExclusion Criteria:\n\n* Unable to speak and understand Danish\n* Severe intellectual disability or mental health disorder that hinders participation\n* Brain metastases,\n* Terminal illness\n* Have had a previous chemotherapy or radiotherapy treatment",true,"7 Years","29 Years",{"count":20,"type":21},"OBSERVATIONAL","The MyBrain study investigates the brain function of children, adolescents and young adults during and after chemo treatment for cancer. The tests include 1) cognitive skills such as memory and attention; 2) the brain's electrical activity; 3) and biological markers related to brain function.\n\nThe aim of the study is to better understand the trajectories of cognitive functioning and measures that have been associated with cognitive impairment in patients treated with chemotherapy.",[27,87,88,89,90,91,92,93,94,95],"Chemotherapeutic Toxicity","Chemo-brain","Cancer","Childhood Cancer","Hodgkin Lymphoma","Non Hodgkin Lymphoma","Testicular Cancer","Sarcoma","Leukemia",[97,98,99,100],"Cognition","Neuropsychology","Electroencephalogram","Biomarkers","RECRUITING","2023-04-24",{"date":104,"type":33},"2023-05-03",{"date":106,"type":33},"2022-03-01",{"date":108,"type":21},"2027-03-01",{"name":110,"class":40},"Rigshospitalet, Denmark","Chemotherapy-related Cognitive Impairment"]